Athenex (Athenex) Interest Expense : $-25.9 Mil (TTM As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Athenex Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Athenex's interest expense for the three months ended in Dec. 2022 was $ -10.8 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2022 was $-25.9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Athenex's Operating Income for the three months ended in Dec. 2022 was $ -13.7 Mil. Athenex's Interest Expense for the three months ended in Dec. 2022 was $ -10.8 Mil. Athenex did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Athenex Interest Expense Historical Data

The historical data trend for Athenex's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Interest Expense Chart

Athenex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-3.58

-6.95

-11.22

-20.65

-25.84

Athenex Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Interest Expense	Get a 7-Day Free Trial															-5.04	-4.52	-4.31	-6.27	-10.75

Athenex Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.9 Mil.

Athenex (OTCPK:ATNXQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Athenex's Interest Expense for the three months ended in Dec. 2022 was $-10.8 Mil. Its Operating Income for the three months ended in Dec. 2022 was $-13.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2022 was $3.1 Mil.

Athenex's Interest Coverage for the quarter that ended in Dec. 2022 is calculated as

Athenex did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Athenex (Athenex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (OTCPK:ATNXQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203

Website

https://www.athenex.com

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Executives

Jinn Wu	director	107 MORGAN LANE, PLAINSBORO NJ 08536
Lau Johnson Yiu Nam	director, officer: CEO and Chairman of the Board
Joe Annoni	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Timothy Devere Cook	officer: See Remarks	C/O ATHENEX, INC., 1001 MAIN STREET,, SUITE 600, BUFFALO NY 14203
Daniel Lang	officer: Pres Cell Therapy, VP Corp Dev	C/O ATHENEX, INC. CONVENTUS BUILDING, 1001 MAIN ST. STE. 600, BUFFALO NY 14203
Jordan Kanfer	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Rudolf Kwan	director, officer: EVP, Chief Medical Officer	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Michael Smolinski	officer: Chief Scientific Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Steven J. Adams	officer: Interim Chief Acct Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Kim Campbell	director	3300 HYLAND AVE, COSTA MESA CA 92626
William Wei Zuo	officer: President, China	3040 POST OAK BLVD, SUITE 1110, HOUSTON TX 77056
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Manson Fok	director	C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Randoll Sze	officer: Chief Financial Officer	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Stephanie A Davis	director	C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203